AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with good INR control (>75%)
Number of subjects: 3587
Study 17296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with moderate INR control (60%-75%)
Number of subjects: 3587
Study 17296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with poor INR control (<60%)
Number of subjects: 3587
Study 16215379 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 69
Study 16215379 — intervention group
Group type: EXPERIMENTAL
Intervention: Late open lung concept (OLC)
Number of subjects: 69
Study 16215379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early open lung concept (OLC)
Number of subjects: 69
Study 12110837 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergens (rPru av 1, rPru av 4, rPru av 3) at concentrations of 10, 50, and 100 microg/mL
Number of subjects: 79
Study 12110837 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergens (rPru av 1, rPru av 4, rPru av 3)
Number of subjects: 79
Study 12110837 — intervention group
Group type: EXPERIMENTAL
Intervention: rPru av 3
Number of subjects: 79
Study 10081532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure with bilateral stimulation of P6 (A)
Number of subjects: 60
Study 10081532 — intervention group
Group type: COMPARATOR
Intervention: Bilateral placebo stimulation (P)
Number of subjects: 60
Study 10081532 — intervention group
Group type: COMPARATOR
Intervention: No acupressure wrist band (R)
Number of subjects: 60
Study 7745065 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG + octreotide
Number of subjects: 28
Study 7745065 — intervention group
Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 28
Study 2382229 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 gm arginine hydrochloride (24.8 gm free arginine) daily
Number of subjects: 36
Study 2382229 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 gm arginine aspartate (17 gm free arginine) daily
Number of subjects: 36
Study 2382229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7193717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized cow milk
Number of subjects: 81
Study 7193717 — intervention group
Group type: COMPARATOR
Intervention: Enfamil or heat-treated cow milk
Number of subjects: 81
Study 30903253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty patients (operated noses)
Number of subjects: 40
Study 30903253 — intervention group
Group type: COMPARATOR
Intervention: Control group (good-looking noses)
Number of subjects: 40
Study 30903253 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (operated and control)
Number of subjects: 40
Study 27611826 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Cervical Nucleoplasty (PCN)
Number of subjects: 34
Study 27611826 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Radio Frequency (PRF)
Number of subjects: 34
Study 27137148 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 *1/*1 genotype (n=3)
Number of subjects: 3
Study 27137148 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 25 mg immediate-release tablets
Number of subjects: 3
Study 24010210 — intervention group
Group type: EXPERIMENTAL
Intervention: sparfloxacin + tamsulosin
Number of subjects: 120
Study 24010210 — intervention group
Group type: EXPERIMENTAL
Intervention: sparfloxacin + herbal decoction
Number of subjects: 120
Study 24010210 — intervention group
Group type: COMPARATOR
Intervention: sparfloxacin
Number of subjects: 120
Study 20975519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Number of subjects: 0
Study 20975519 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules
Number of subjects: 0
Study 20975519 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patch vs oral administration
Number of subjects: 0
Study 19272499 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel formulation containing 3% hydroxypropyl methylcellulose and 1.5% methyl cellulose
Number of subjects: 24
Study 19272499 — intervention group
Group type: EXPERIMENTAL
Intervention: Four different gel formulations
Number of subjects: 24
Study 17437831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin
Number of subjects: 217
Study 15490983 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin monotherapy
Number of subjects: 102
Study 15490983 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin plus ceftazidime
Number of subjects: 102
Study 15490983 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin plus netilmycin (historic group)
Number of subjects: 102
Study 11479059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program for families with a child affected by cystic fibrosis
Number of subjects: 16
Study 9446960 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional structure labor organizations favoring perceptual abilities in females
Number of subjects: 0
Study 9446960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels in the hierarchy of functional structure organizations
Number of subjects: 0
Study 7935815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride (beta-adrenergic receptor antagonist)
Number of subjects: 0
Study 7935815 — intervention group
Group type: COMPARATOR
Intervention: Control (emotionally neutral story)
Number of subjects: 0
Study 3162247 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian double-headed toothbrush
Number of subjects: 44
Study 3162247 — intervention group
Group type: COMPARATOR
Intervention: Single-headed brush
Number of subjects: 44
Study 29530607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialendoscopy‐assisted stone removal via extraoral incision with preservation of the SMG
Number of subjects: 40
Study 29530607 — intervention group
Group type: COMPARATOR
Intervention: Traditional SMG resection
Number of subjects: 40
Study 27220675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol with 600 mg of Mg sulfate
Number of subjects: 816
Study 27220675 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulized salbutamol
Number of subjects: 816
Study 25135766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g UPSN per day for 14 days
Number of subjects: 0
Study 25135766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g UPSN per day for 14 days
Number of subjects: 0
Study 25135766 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g calcium carbonate placebo per day for 14 days
Number of subjects: 0
Study 22846251 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms feedback intervention
Number of subjects: 3000
Study 20723221 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkFit Program
Number of subjects: 586
Study 17588503 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Based Behavioral Group Intervention
Number of subjects: 90
Study 17588503 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Only Behavioral Group Intervention
Number of subjects: 90
Study 17588503 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 90
Study 15826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning by watching a model respond to a 6-item unique sequence.
Number of subjects: 0
Study 15826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Free generation and recognition tests after observing the finger movement sequence.
Number of subjects: 0
Study 15826229 — intervention group
Group type: COMPARATOR
Intervention: Control group who performed an unrelated task or observed a model responding to random targets.
Number of subjects: 0
Study 12096299 — intervention group
Group type: COMPARATOR
Intervention: Esophagectomy alone
Number of subjects: 75
Study 12096299 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus selective surgery
Number of subjects: 75
Study 12096299 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 75
Study 12096299 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration for selective surgery
Number of subjects: 75
Study 12096299 — intervention group
Group type: COMPARATOR
Intervention: Overall surgical mortality
Number of subjects: 75
Study 12096299 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative endoscopic biopsy
Number of subjects: 75
Study 9876294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 30% of VO2peak
Number of subjects: 12
Study 9876294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 50% of VO2peak
Number of subjects: 12
Study 9876294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 80% of VO2peak
Number of subjects: 12
Study 9876294 — intervention group
Group type: COMPARATOR
Intervention: Control trial (non-exercise)
Number of subjects: 12
Study 8570774 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl (10 mg p.o., q.d.)
Number of subjects: 17
Study 8570774 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.5 mg)
Number of subjects: 17
Study 8570774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-deprenyl and Physostigmine
Number of subjects: 17
Study 8570774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2232919 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and feedback using an electronic device that records the time and day pills are removed
Number of subjects: 93
Study 2232919 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback about serum lithium levels and patterns of removing medications from the monitoring device
Number of subjects: 93
Study 2232919 — intervention group
Group type: COMPARATOR
Intervention: Feedback about serum lithium levels only (Control)
Number of subjects: 93
Study 555480 — intervention group
Group type: EXPERIMENTAL
Intervention: Presleep tension alone
Number of subjects: 20
Study 555480 — intervention group
Group type: EXPERIMENTAL
Intervention: Presleep tension and intrusive cognitions
Number of subjects: 20
Study 555480 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of sleep
Number of subjects: 20
Study 555480 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 subjects)
Number of subjects: 20
Study 31373647 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning classifier for smoking vs nonsmoking environments
Number of subjects: 169
Study 31373647 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning classifier trained on Durham images
Number of subjects: 169
Study 31373647 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning classifier trained on Pittsburgh images
Number of subjects: 169
Study 31373647 — intervention group
Group type: COMPARATOR
Intervention: Expert classification
Number of subjects: 169
Study 31373647 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported craving levels
Number of subjects: 169
Study 28219338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mixed surveillance programme (exercise at home monitored with NUUBO® device, walking at 70% HRR for 1 hour/day, 5-7 days/week for 2 months)
Number of subjects: 28
Study 28219338 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation in hospital (control group)
Number of subjects: 28
Study 28219338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mixed surveillance programme
Number of subjects: 28
Study 28219338 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation in hospital
Number of subjects: 28
Study 26212318 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational LARC script during postpartum hospitalization
Number of subjects: 324
Study 26212318 — intervention group
Group type: COMPARATOR
Intervention: Not receiving educational LARC script
Number of subjects: 324
Study 26212318 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-use of LARC among interested women
Number of subjects: 324
Study 26212318 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive methods used instead of LARC
Number of subjects: 324
Study 23908148 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 14
Study 23908148 — intervention group
Group type: COMPARATOR
Intervention: One night of sleep
Number of subjects: 14
Study 21767103 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (immediate therapy)
Number of subjects: 1763
Study 21767103 — intervention group
Group type: COMPARATOR
Intervention: Delayed antiretroviral therapy (after decline in CD4 count or onset of symptoms)
Number of subjects: 1763
Study 19551881 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information plus patient navigation (TPN)
Number of subjects: 487
Study 19551881 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 487
Study 17116721 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (HK-LP) 10 mg daily for 12 weeks
Number of subjects: 60
Study 14746696 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradicating treatment with omeprazole, amoxicillin, and clarithromycin for 7 days (group A, n = 47)
Number of subjects: 93
Study 14746696 — intervention group
Group type: COMPARATOR
Intervention: Placebo, amoxicillin, and clarithromycin for 7 days (group B, n = 46)
Number of subjects: 93
Study 14746696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 93
Study 11210244 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 36
Study 11210244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride treatment
Number of subjects: 36
Study 11210244 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA treatment
Number of subjects: 36
Study 11210244 — intervention group
Group type: COMPARATOR
Intervention: Root planing only
Number of subjects: 36
Study 9505913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stent (group A)
Number of subjects: 60
Study 9505913 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty alone (group B)
Number of subjects: 60
Study 7529754 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bleomycin 1% in dimethylsulphoxide (DMSO) applied for 5 minutes for 14 consecutive days
Number of subjects: 22
Study 7529754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier)
Number of subjects: 22
Study 3588048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol 0.5 micrograms/kg
Number of subjects: 12
Study 3588048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol 1.0 micrograms/kg
Number of subjects: 12
Study 3588048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol 1.5 micrograms/kg
Number of subjects: 12
Study 3588048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31494306 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIP)
Number of subjects: 28
Study 31494306 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol (Control)
Number of subjects: 28
Study 30567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 44
Study 30567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 44
Study 30567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 44
Study 30567914 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 44
Study 26272524 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter contact force (CF) during radiofrequency ablation
Number of subjects: 36
Study 26272524 — intervention group
Group type: EXPERIMENTAL
Intervention: CF threshold of >8 g
Number of subjects: 36
Study 26272524 — intervention group
Group type: EXPERIMENTAL
Intervention: CF threshold of >12 g
Number of subjects: 36
Study 24093756 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Training Instrument (MATI)
Number of subjects: 0
Study 24093756 — intervention group
Group type: COMPARATOR
Intervention: Usual model medical follow-up (Control)
Number of subjects: 0
Study 24093756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MATI and Control
Number of subjects: 0
Study 22689416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cholesterol-lowering therapy with pitavastatin (target LDL-C; 80 mg/dl)
Number of subjects: 303
Study 22689416 — intervention group
Group type: COMPARATOR
Intervention: Moderate cholesterol-lowering therapy with pitavastatin (target LDL-C; 100 mg/dl)
Number of subjects: 303
Study 21612319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azelaic acid 5% and clindamycin 2% (AA-Clin)
Number of subjects: 150
Study 21612319 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 2%
Number of subjects: 150
Study 21612319 — intervention group
Group type: COMPARATOR
Intervention: Azelaic acid 5%
Number of subjects: 150
Study 18279043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection alone
Number of subjects: 0
Study 18279043 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection and tuberculosis
Number of subjects: 0
Study 18279043 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 0
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Superficial vein reflux detected by ultrasonography
Number of subjects: 100
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Primary venous insufficiency
Number of subjects: 100
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Overweight and obesity
Number of subjects: 100
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Primary valvular insufficiency
Number of subjects: 100
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Secondary valvular insufficiency (post-thrombotic, post-traumatic)
Number of subjects: 100
Study 16871763 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 100
Study 12888870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin infusions
Number of subjects: 0
Study 12888870 — intervention group
Group type: COMPARATOR
Intervention: No antithrombin treatment (control)
Number of subjects: 0
Study 10877248 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment with optimized doses based on skin pigmentation measurements
Number of subjects: 20
Study 10877248 — intervention group
Group type: COMPARATOR
Intervention: Conventional UVB treatment regimen with fixed dose increments
Number of subjects: 20
Study 1563884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (10 capsules, 3 g per day, containing 1.8 g eicosapentaenoic acid and 1.2 g docosahexaenoic acid)
Number of subjects: 107
Study 1563884 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (aspirin and calcium blockers)
Number of subjects: 107
Study 1563884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 107
Study 1563884 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 107
Study 3528402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 122
Study 3528402 — intervention group
Group type: COMPARATOR
Intervention: Surgical oophorectomy
Number of subjects: 122
Study 30068323 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D heart model
Number of subjects: 63
Study 30068323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 3D heart model)
Number of subjects: 63
Study 27741340 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 27741340 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 27741340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24934214 — intervention group
Group type: EXPERIMENTAL
Intervention: Context A1B1 during acquisition training with cue Z
Number of subjects: 0
Study 24934214 — intervention group
Group type: EXPERIMENTAL
Intervention: Context A2B2 during extinction trials with cue Z
Number of subjects: 0
Study 22612765 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme (ITOHEP) based on cognitive behavioural strategies
Number of subjects: 113
Study 22612765 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment programme (ST)
Number of subjects: 113
Study 22612765 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme (ITOHEP)
Number of subjects: 113
Study 20167644 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training program
Number of subjects: 30
Study 20167644 — intervention group
Group type: COMPARATOR
Intervention: Control program (flexibility and relaxation training)
Number of subjects: 30
Study 18242145 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 100 mg once daily
Number of subjects: 152
Study 18242145 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Number of subjects: 152
Study 18242145 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 152
Study 20026883 — intervention group
Group type: EXPERIMENTAL
Intervention: Element ankle brace with subtalar locking system
Number of subjects: 19
Study 20026883 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ankle brace
Number of subjects: 19
Study 20026883 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO ankle brace
Number of subjects: 19
Study 20026883 — intervention group
Group type: COMPARATOR
Intervention: No brace condition
Number of subjects: 19
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical skin check
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin self-examination
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: History of clinical skin examination
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about skin cancer
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal history of skin cancer
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: High susceptibility towards skin cancer
Number of subjects: 3110
Study 15207981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 3110